KTTA vs. SHPH, TENX, CVKD, VCNX, HEPA, IBIO, BFRI, PULM, ASLN, and AIMD
Should you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Shuttle Pharmaceuticals (SHPH), Tenax Therapeutics (TENX), Cadrenal Therapeutics (CVKD), Vaccinex (VCNX), Hepion Pharmaceuticals (HEPA), iBio (IBIO), Biofrontera (BFRI), Pulmatrix (PULM), ASLAN Pharmaceuticals (ASLN), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
Pasithea Therapeutics (NASDAQ:KTTA) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 5 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.87 beat Shuttle Pharmaceuticals' score of 0.65 indicating that Pasithea Therapeutics is being referred to more favorably in the media.
Pasithea Therapeutics received 2 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users.
23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 14.1% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 40.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Pasithea Therapeutics' return on equity of -60.06% beat Shuttle Pharmaceuticals' return on equity.
Shuttle Pharmaceuticals has lower revenue, but higher earnings than Pasithea Therapeutics.
Pasithea Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500.
Summary
Pasithea Therapeutics beats Shuttle Pharmaceuticals on 7 of the 9 factors compared between the two stocks.
Get Pasithea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pasithea Therapeutics Competitors List
Related Companies and Tools
